Apricus Terminates Fispemifene Clinical Program, Cuts Workforce

Apricus Biosciences has cut 30 percent of its workforce — including part of its executive team — following an unsuccessful Phase 2b trial evaluating fispemifene in men with secondary hypogonadism and sexual dysfunction.
Source: Drug Industry Daily